Trial Profile
A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms HPTN 077
- 10 Aug 2022 Results of an analysis assessed long-acting cabotegravir pharmacokinetics published in the British Journal of Clinical Pharmacology
- 12 May 2020 Results published in the JAIDS
- 07 Mar 2019 Results assessing Cabotegravir is not associated with weight gain presented at the 26th Conference on Retroviruses and Opportunistic Infections